Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial.

CONCLUSIONS: Durvalumab plus tremelimumab did not increase CD8+TIL density more than durvalumab alone did. The observed safety and activity support further investigation of neoadjuvant checkpoint inhibitor for OPC. PMID: 32269052 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32269052?dopt=Abstract

Source: Clin Med Res - April 7, 2020 Category: Research Authors: Ferrarotto R, Bell D, Rubin ML, Hutcheson KA, Johnson JM, Goepfert RP, Phan J, Elamin YY, Torman Karagiannis DT, Warneke CL, Hessel AC, Garden AS, Myers JN, Johnson FM, Lee JJ, Sikora A, Gillison ML, Glisson BS, Gross ND Tags: Clin Cancer Res Source Type: research